TRCT
LSTA icon

Tower Research Capital (TRC)’s Lisata Therapeutics LSTA Stock Holding History

Tower Research Capital (TRC)’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93K Sell
785
-1,767
-69% -$7.29K ﹤0.01% 4247
2025
Q4 		$4.75K Buy
2,552
+881
+53% +$1.96K ﹤0.01% 4181
2025
Q3 		$4.38K Buy
1,671
+348
+26% +$873 ﹤0.01% 4361
2025
Q2 		$3.84K Sell
1,323
-884
-40% -$2.13K ﹤0.01% 4427
2025
Q1 		$5.19K Buy
2,207
+292
+15% +$790 ﹤0.01% 4144
2024
Q4 		$5.71K Buy
1,915
+389
+25% +$1.11K ﹤0.01% 4255
2024
Q3 		$4.58K Buy
1,526
+1,086
+247% +$3.42K ﹤0.01% 4491
2024
Q2 		$1.53K Sell
440
-413
-48% -$1.26K ﹤0.01% 5144
2024
Q1 		$2.66K Sell
853
-176
-17% -$521 ﹤0.01% 4999
2023
Q4 		$2.81K Buy
+1,029
New +$2.42K ﹤0.01% 5161
2023
Q3 		– Sell
-1,060
Closed -$3.92K – 6115
2023
Q2 		$3.92K Buy
1,060
+369
+53% +$1.34K ﹤0.01% 5009
2023
Q1 		$2K Sell
691
-905
-57% -$3.03K ﹤0.01% 5373
2022
Q4 		$4K Buy
+1,596
New +$5.86K ﹤0.01% 5032
2022
Q3 		– Sell
-1,216
Closed -$10K – 6312
2022
Q2 		$10K Buy
1,216
+623
+105% +$5.13K ﹤0.01% 4462
2022
Q1 		$6K Buy
593
+487
+459% +$5.57K ﹤0.01% 4897
2021
Q4 		$1K Buy
106
+96
+960% +$1.48K ﹤0.01% 5848
2021
Q3 		$0 Buy
+10
New +$196 ﹤0.01% 5991
2021
Q1 		– Sell
-331
Closed -$7K – 5572
2020
Q4 		$7K Sell
331
-552
-63% -$13.1K ﹤0.01% 4495
2020
Q3 		$24K Buy
883
+339
+62% +$10.7K ﹤0.01% 3803
2020
Q2 		$15K Buy
+544
New +$16K ﹤0.01% 3815
2019
Q3 		– Sell
-234
Closed -$8K – 4339
2019
Q2 		$8K Buy
+234
New +$10.4K ﹤0.01% 2690
2017
Q3 		– Sell
-9
Closed -$1K – 4003
2017
Q2 		$1K Sell
9
-11
-55% -$777 ﹤0.01% 2498
2017
Q1 		$2K Buy
+20
New +$1.39K ﹤0.01% 2634
2016
Q1 		– Sell
-4
Closed -$1K – 4588
2015
Q4 		$1K Sell
4
-7
-64% -$1.28K ﹤0.01% 4108
2015
Q3 		$2K Buy
11
+7
+175% +$1.76K ﹤0.01% 3357
2015
Q2 		$1K Sell
4
-19
-83% -$7.06K ﹤0.01% 4018
2015
Q1 		$9K Buy
+23
New +$12.5K ﹤0.01% 2867
2014
Q4 		– Sell
-20
Closed -$16K – 4383
2014
Q3 		$16K Sell
20
-104
-84% -$91K ﹤0.01% 2484
2014
Q2 		$121K Buy
124
+117
+1,671% +$114K 0.02% 802
2014
Q1 		$7K Sell
7
-34
-83% -$36.9K ﹤0.01% 2969
2013
Q4 		$42K Buy
41
+37
+925% +$36.6K 0.01% 1537
2013
Q3 		$6K Buy
+4
New +$4.44K ﹤0.01% 3551

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Tower Research Capital (TRC)'s LSTA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Lisata Therapeutics (LSTA) stake by 69% in Q1 2026, selling an estimated $7.29K and leaving 785 shares worth $3.93K. The position accounts for ﹤0.01% of the portfolio, ranked #4247.

Tower Research Capital (TRC) first reported a position in LSTA in Q3 2013 and has held it in 32 quarters since. The position peaked at $121K in Q2 2014. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Tower Research Capital (TRC) held 785 shares of Lisata Therapeutics worth $3.93K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,767 Lisata Therapeutics shares in Q1 2026, an estimated $7.29K.
  • Lisata Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4247 holding.
  • Tower Research Capital (TRC) first reported a position in Lisata Therapeutics in Q3 2013 and has held it in 32 quarters since.
  • Tower Research Capital (TRC)'s Lisata Therapeutics position peaked at $121K in Q2 2014.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.